Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldafermin in compensated NASH cirrhosis
NCT04210245Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Mar 2020
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of aldafermin in Nonalcoholic steatohepatitis (NASH) and Liver cirrhosis (LC) (4 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Change From Baseline in Enhanced Liver Fibrosis Score at 48 weeks. Started Mar 2020; status: completed.
02
Drugs
aldafermin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT04210245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04210245.